A354390 Stock Overview
Baskhanbio Pharma Inc. suministra en Corea del Sur analgésicos para antes y después de la cirugía y dispositivos médicos para procesos quirúrgicos.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Baskhanbio Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩7,800.00 |
52 Week High | ₩9,200.00 |
52 Week Low | ₩5,070.00 |
Beta | 0 |
1 Month Change | 21.88% |
3 Month Change | 13.87% |
1 Year Change | 36.84% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -33.90% |
Recent News & Updates
Recent updates
Shareholder Returns
A354390 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 8.3% | -5.8% | -1.5% |
1Y | 36.8% | 10.1% | 7.5% |
Rentabilidad frente al sector: A354390 superó al sector KR Pharmaceuticals , que obtuvo un rendimiento del 23% el año pasado.
Rentabilidad vs. Mercado: A354390 superó al mercado KR, que obtuvo un rendimiento del 10.6% el año pasado.
Price Volatility
A354390 volatility | |
---|---|
A354390 Average Weekly Movement | 7.6% |
Pharmaceuticals Industry Average Movement | 4.7% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 12.0% |
10% least volatile stocks in KR Market | 2.4% |
Precio estable de las acciones: A354390 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: A354390La volatilidad semanal ha disminuido de 13% a 8% en el último año.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | https://baskhanbio.com |
Baskhanbio Pharma Inc. suministra en Corea del Sur analgésicos para antes y después de la cirugía y dispositivos médicos para procesos quirúrgicos. La empresa tiene su sede en Anseong (Corea del Sur).
Baskhanbio Pharma Inc. Fundamentals Summary
A354390 fundamental statistics | |
---|---|
Market cap | ₩54.74b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A354390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A354390 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A354390 perform over the long term?
See historical performance and comparison